9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Estimated reading time: < 1 min

Condition: Peritoneal Mesothelioma

Estimated Enrollment: 15

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Incidence and severity of adverse events as assessed by CTCAE v.5.0,  Response Evaluation Criteria in Solid Tumors (RECIST),  Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST),

Interventions: MCY-M11,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Sequential Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: December 2020

Completion Date: December 2020

Last  Posted Date: September 20, 2018

Location: National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT03608618

Was this article helpful?
Dislike 0